Systems biology approach to predict optimal therapeutic strategies for aggressive prostate cancer

Antonina Mitrofanova¹, 8,*, Alvaro Aytes²,*, Min Zou², Michael M. Shen³, ⁴, ⁷, Cory Abate-Shen¹, ², ⁵, ⁷# and Andrea Califano¹, ⁶, ⁷, #

Departments of ¹Systems Biology, ²Urology, ³Medicine, ⁴Genetics & Development, ⁵Pathology & Cell Biology, and ⁶Biochemistry & Molecular Biophysics, and ⁷The Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, NY 10032; Department of ⁸Health Informatics, SHP, RBHS, Rutgers The State University of New Jersey, NJ, 07107
*These authors contributed equally to this study
#Authors for correspondence

Background: Recent large-scale genomic analyses of cancer have led to the identification of “actionable” driver genes that represent therapeutically accessible targets, including oncogene and non-oncogene dependencies. However, the accurate and efficient identification of drugs and drug combinations that target such drivers represents a major challenge, particularly for transcriptional regulators, which are generally considered pharmacologically inaccessible for therapeutic targeting. Here we introduce an approach that uses in vivo drug perturbation data from Genetically Engineered Mouse models of aggressive prostate cancer to predict drug efficacy in human patients.

Methods: We have developed a novel computational systems approach to analyze gene expression profiles of pharmacological perturbations in mouse models of aggressive prostate cancer and identified drugs and drug combinations that inhibit the transcriptional activity of the key regulatory genes that drive prostate cancer malignancy, namely FOXM1 and CENPF.

Results: Validation of our computational predictions in mouse and human prostate cancer experimental essays confirmed the specificity and synergy of a predicted drug combination to abrogate activity of FOXM1 and CENPF and inhibit tumorigenicity. Furthermore, computational analysis of transcriptional regulatory alterations after the drug administration identified treatment-responsive genes, which are potential biomarkers of patient response to the therapy.

Conclusions: This approach may allow systematic identification of drugs targeting specific tumor dependencies, and thus might potentially provide direct therapeutic benefits for prostate cancer patients with specific transcriptional dysregulations.

Conflict of Interest: Andrea Califano is a founder and stockholder of Darwin Health and Therasis and a consultant for Dow AgroSciences, Thermo Fisher Scientific, and Cancer Genetics Inc.

Funding: This work was supported by the Prostate Cancer Foundation Young Investigator Award (A.M.), grants CA173481 (to C.A.-S.), U01 CA084294 (to C.A.-S., M.M.S., and A.C.), U54 CA121852 (to A.C., C.A.-S., M.M.S.), P01 CA154293 (to M.M.S. and C.A.-S.), U01HL111566-02S2 (to A.C.) and U01CA168426 (to A.C.). A.A. was a recipient of a Marie Curie International Outgoing Fellowship (PIOF-GA-2009-253290), co-sponsored with the Catalan Institute of Oncology-Bellvitge Institute for Biomedical Research, Barcelona, Spain, and a recipient of a pilot award from the Irving Institute for Clinical and Translational Research at Columbia University supported by the National Center for Advancing Translational Sciences, NIH (UL1 TR000040). C.A.-S. is an American Cancer Society Research Professor supported in part by a generous gift from the F.M. Kirby Foundation.